Currently, one prospective trial for CXCR4-directed RLT, which will investigate the activity and tolerable dose and side effects of [177Lu/90Y]Pentixather RLT in patients with MM or NHL (COLPRIT trial, EudraCT 2015-001817-28), is in preparation. This evidence concerns the gene CXCR4 and Miyoshi myopathy.